Testing for hereditary breast and ovarian cancer in the southeastern United States

被引:15
|
作者
Miron, A
Schildkraut, JM
Rimer, BK
Winer, EP
Skinner, CS
Futreal, PA
Culler, D
Calingaert, B
Clark, S
Marcom, PK
Iglehart, JD
机构
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Family & Community Med, Durham, NC 27710 USA
[4] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1097/00000658-200005000-00002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objectives To detail characterization of mutations and uncharacterized variants in the breast cancer susceptibility genes BRCA1 and BRCA2, as observed in a population of breast cancer patients from the southeastern United States, and to examine baseline characteristics of women referred for counseling and testing and provide a preliminary look at how counseling and testing affected intentions toward prophylactic surgery, Background Mutations in the BRCA1 and BRCA2 genes give rise to a dramatically increased risk of developing breast or ovarian cancer or both. There are many reports about special populations in which deleterious mutations are present ata high frequency. it is useful to study these genes in more heterogeneous populations, reflecting different geographic regions. Interest in preventive surgery for gene carriers is high in women and their surgeons. Methods Women were recruited through a prospective clinical trial of counseling and free genetic testing. BRCA1 and BRCA2 were screened for mutations using standard techniques, and results were given to participants. Baseline questionnaires determined interest in preventive surgery at the beginning of the study. Follow-up questionnaires for those who completed testing surveyed interest in prophylactic surgery after counseling and receiving test results, Results OC 213 women who completed counseling and testing, 44 (20.6%) had 29 separate mutations; there were II Jewish women carrying three founder mutations. Twenty-eight women (13.1%) had uncharacterized variants in BRCA1 or BRCA2; nine were not previously reported. Women overestimated their chances of possessing a deleterious gene mutation compared to a statistical estimate of carrier risk, A number of women changed their intentions toward preventive surgery after genetic counseling and testing, Conclusions Hereditary breast cancer due to mutations in BRCA1 and BRCA2 was a heterogeneous syndrome in the southeastern United States. Most mutations were seen just once, and uncharacterized variants were common and of uncertain clinical significance. in general, positive test results tended to reinforce intentions toward prophylactic surgery. in contrast, women not interested in surgery at the time of entry tended to remain reluctant after testing and counseling.
引用
收藏
页码:624 / 632
页数:9
相关论文
共 50 条
  • [21] The uptake of presymptomatic genetic testing for hereditary breast and/or ovarian cancer syndrome
    Barbara, Babuder
    Simona, Hotujec
    Ana, Blatni
    Ksenija, Strojnik
    Marta, Banjac
    Srdjan, Novakovic
    Mateja, Krajc
    ONKOLOGIJA, 2021, 25 (02) : 16 - 23
  • [22] Ethics of predictive DNA-testing for hereditary breast and ovarian cancer
    de Wert, G
    PATIENT EDUCATION AND COUNSELING, 1998, 35 (01) : 43 - 52
  • [23] Economic impact of multigene panel testing for hereditary breast and ovarian cancer
    Byfield, Stacey Dacosta
    Wei, Helen
    DuCharme, Mary
    Lancaster, Johnathan M.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (03) : 207 - 217
  • [24] Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients
    Lumish, Heidi S.
    Steinfeld, Hallie
    Koval, Carrie
    Russo, Donna
    Levinson, Elana
    Wynn, Julia
    Duong, James
    Chung, Wendy K.
    JOURNAL OF GENETIC COUNSELING, 2017, 26 (05) : 1116 - 1129
  • [25] Psychometric Testing of the Decisional Conflict Scale Genetic Testing Hereditary Breast and Ovarian Cancer
    Katapodi, Maria C.
    Munro, Michelle L.
    Pierce, Penny F.
    Williams, Reg A.
    NURSING RESEARCH, 2011, 60 (06) : 368 - 377
  • [26] Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States
    Guzauskas, Gregory F.
    Garbett, Shawn
    Zhou, Zilu
    Spencer, Scott J.
    Smith, Hadley S.
    Hao, Jing
    Hassen, Dina
    Snyder, Susan R.
    Graves, John A.
    Peterson, Josh F.
    Williams, Marc S.
    Veenstra, David L.
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [27] Genetic testing for hereditary breast and ovarian cancer in cancer patients: family communication and knowledge
    Claes, E
    Evers-Kiebooms, G
    Boogaerts, A
    Decruyenaere, M
    Denayer, L
    Legius, E
    PSYCHO-ONCOLOGY, 2001, 10 (04) : S39 - S39
  • [28] Hereditary Gastric Cancer Is Linked With Hereditary Breast and Ovarian Cancer
    Hayashi, Takuma
    Sano, Kenji
    Okada, Mako
    Ura, Takashi
    Konishi, Ikuo
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (04) : 722 - 730
  • [29] Correction to: Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario
    Jordan Lerner-Ellis
    Chloe Mighton
    Conxi Lazaro
    Nicholas Watkins
    Vanessa Di Gioacchino
    Andrew Wong
    Martin C. Chang
    George S. Charames
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2487 - 2487
  • [30] Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center
    Chapman-Davis, Eloise
    Zhou, Zhen Ni
    Fields, Jessica C.
    Frey, Melissa K.
    Jordan, Bailey
    Sapra, Katherine J.
    Chatterjee-Paer, Sudeshna
    Carlson, Ann D.
    Holcomb, Kevin M.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (01) : 35 - 42